Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children’s Oncology Group Study ANBL0531

PURPOSE: The primary objective of the Children’s Oncology Group study ANBL0531 (ClinicalTrials.gov identifier: NCT00499616) was to reduce therapy for subsets of patients with intermediate-risk neuroblastoma using a biology- and response-based algorithm to assign treatment duration while maintaining...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Twist, Clare J., Schmidt, Mary Lou, Naranjo, Arlene, London, Wendy B., Tenney, Sheena C., Marachelian, Araz, Shimada, Hiroyuki, Collins, Margaret H., Esiashvili, Natia, Adkins, E. Stanton, Mattei, Peter, Handler, Michael, Katzenstein, Howard, Attiyeh, Edward, Hogarty, Michael D., Gastier-Foster, Julie, Wagner, Elizabeth, Matthay, Katherine K., Park, Julie R., Maris, John M., Cohn, Susan L.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2019
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6881103/
https://ncbi.nlm.nih.gov/pubmed/31386611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00919
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires